Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes (CaDDM)
This study is currently recruiting participants.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), January 2009
Sponsors and Collaborators: National Institutes of Health (NIH)
Tufts Medical Center
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00436475
  Purpose

The purpose of the randomized trial is to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2 diabetes.


Condition Intervention Phase
Glucose Intolerance
Type 2 Diabetes Mellitus
Metabolic Syndrome
 Drug: Vitamin D3 2,000 IU orally once daily
Drug: Calcium Carbonate 400 mg orally twice daily
Drug: Vitamin D3-Placebo
Drug: Calcium-Placebo
 Phase I
Phase II

MedlinePlus related topics: Calcium Diabetes
Drug Information available for: Calcium gluconate Vitamin D Ergocalciferol Calcium carbonate Cholecalciferol Dextrose
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Efficacy Study
Official Title: Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Insulin sensitivity, Insulin secretion and Disposition Index [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • glucose tolerance (fasting, after OGTT), systemic inflammation, lipoprotein profile, blood pressure, body weight and body composition [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
  • Genetic studies on Vitamin D related genes and risk of type 2 diabetes and cardiometabolic outcomes [ Time Frame: 4 months ] [ Designated as safety issue: No ]
  • To collect and archive biological specimens (serum, plasma, DNA) so that they can be used for testing of new hypotheses either within the parent stud or through future ancillary studies. [ Time Frame: 0 and 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 112
Study Start Date: September 2007
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
Drug: Vitamin D3 2,000 IU orally once daily
Vitamin D3 2,000 IU orally once daily
Drug: Calcium Carbonate 400 mg orally twice daily
Calcium Carbonate 400 mg orally twice daily
2
Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
Drug: Vitamin D3 2,000 IU orally once daily
Vitamin D3 2,000 IU orally once daily
Drug: Calcium-Placebo
Calcium-Placebo
3
Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
Drug: Calcium Carbonate 400 mg orally twice daily
Calcium Carbonate 400 mg orally twice daily
Drug: Vitamin D3-Placebo
Vitamin D3-Placebo
4
Vitamin D3-Placebo plus Calcium-Placebo
Drug: Vitamin D3-Placebo
Vitamin D3-Placebo
Drug: Calcium-Placebo
Calcium-Placebo

Detailed Description:

There is animal and human observational evidence to suggest that vitamin D and calcium are important in modifying t2DM risk but there are critical gaps in our knowledge about the clinical magnitude of the association with t2DM and potential mechanisms in humans. We are conducting a randomized trial to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for t2DM. We anticipate that the research proposed in this application is significant because it will provide the basis for defining feasible nutritional interventions that promotes prevention of t2DM. Based on the results of the proposed studies and future work in this area, vitamin D and calcium supplementation can assume an important role in the treatment of t2DM and in the prevention of the disease in the 41 million Americans who are at risk of developing t2DM.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ethnicity: all ethnic groups
  • Gender: men and women

  • Age

    1. Lower age limit: 40 years inclusive
    2. Upper age limit: NONE

  • BMI

    1. Lower BMI limit: 25 inclusive
    2. Upper BMI limit: 40 inclusive

  • Glucose Intolerance / Mild Diabetes defined as

    1. Fasting glucose ≥100 mg/dl OR
    2. 2-hr glucose after OGTT ≥140 mg/dl OR
    3. 5.8 ≤ Hemoglobin A1c ≤ 7

Major Exclusion Criteria:

  • Diabetes requiring pharmacotherapy
  • Smoking
  • Hyperparathyroidism
  • Hypercalcemia (Calcium > 10.5 mg/dl)
  • Kidney stone
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00436475

Contacts
Contact: Marie Francia, MD 617-636-2834 caddm@tufts-nemc.org
Contact: Anastassios Pittas, MD 617-636-2834 caddm@tufts-nemc.org

Locations
United States, Massachusetts
Tufts-New England Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Marie Francia, MD     617-636-2834     caddm@tufts-nemc.org    
Contact: Noah Lubowsky, MD     617-636-2834     caddm@tufts-nemc.org    
Principal Investigator: Anastassios G Pittas, MD MS            
Sub-Investigator: Bess Dawson-Hughes, MD            
Sub-Investigator: Frank Hu, MD PhD            
Sponsors and Collaborators
National Institutes of Health (NIH)
Tufts Medical Center
Investigators
Principal Investigator: Anastassios G Pittas, MD MS Tufts Medical Center
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Publications:
Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017-29. Epub 2007 Mar 27. Review.
Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007 Apr;30(4):980-6. Epub 2007 Feb 2.
Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006 Mar;29(3):650-6.

Responsible Party: Tufts-New England Medical Center ( Anastassios G. Pittas )
Study ID Numbers: DK76092, DK76092
Study First Received: February 16, 2007
Last Updated: January 5, 2009
ClinicalTrials.gov Identifier: NCT00436475  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Glucose intolerance
Type 2 diabetes mellitus
Metabolic syndrome

Study placed in the following topic categories:
Cholecalciferol
Metabolic Diseases
Glucose Intolerance
Diabetes Mellitus
Ergocalciferols
Endocrine System Diseases
Calcium Carbonate
 Calcium, Dietary
Hyperglycemia
Vitamin D
Diabetes Mellitus, Type 2
Endocrinopathy
Glucose Metabolism Disorders
Metabolic disorder

Additional relevant MeSH terms:
Pathologic Processes
Disease
Molecular Mechanisms of Pharmacological Action
Growth Substances
Vitamins
Syndrome
 Physiological Effects of Drugs
Antacids
Bone Density Conservation Agents
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services